Democritus University of Thrace (DUTH)
Χορήγηση σιδηροθεραπείας από του στόματος σε παιδιά με μεμονωμένη σιδηροπενία ή σιδηροπενική αναιμία και συσχέτιση της θεραπείας αυτής με τυχόν πρόκληση φλεγμονής στον εντερικό βλεννογόνο
Abstract
dc:descriptionIntroduction: Iron deficiency is the most common nutritional disorder worldwide and can manifest with or without anemia, causing a variety of symptoms that affect patients' quality of life. For every patient with iron deficiency anemia (IDA), there is at least one more with iron deficiency without anemia (IDWA). Iron is particularly important during childhood, as it plays a crucial role in the development of the central nervous system. Clinical manifestations of iron deficiency vary depending on age, the presence and severity of anemia, any coexisting morbidities, and the rate of onset. Strategies for controlling iron deficiency anemia include iron supplementation and home-based fortification of meals with micronutrient powders (MNPs). Oral iron therapy is the first-line treatment for iron deficiency and IDA in children, due to its effectiveness, safety, and low cost. Many oral iron products at various formulations and doses are available. However, absorption of orally administered iron is generally poor and may be further reduced by certain medications and food intake, making oral iron therapy challenging. Additionally, gastrointestinal side effects often diminish compliance with therapy. Sucrosomial iron (SI) is an innovative formulation which is absorbed through paracellular and transcellular routes (M cells), thereby bypassing the conventional iron absorption pathway. Due to its behavior in the gastrointestinal tract, SI is well tolerated and highly bioavailable compared to conventional iron salts; however, data on its safety and efficacy in children are limited. Regarding home fortification with MNPs, iron is incorporated into a lipid matrix that minimizes its impact on the taste and appearance of food. This approach appears to reduce the risk of anemia and iron deficiency; however, its safety remains unclear, as it may negatively affect the gut microbiota by increasing the abundance of enteropathogens, while also raising fecal calprotectin levels and the incidence of diarrhea in infants, according to some studies. Aims: To determine whether oral iron therapy in children with IDWA or IDA is associated with intestinal inflammation. Furthermore, the safety and efficacy of SI were evaluated in comparison with a preparation containing iron (III)-hydroxide polymaltose complex (IPC). Methods: Children aged 6 months to 16 years with IDA or IDWA were randomly assigned to receive either IPC 5 mg/kg once daily (maximum daily dose 100 mg) or SI 1.4 mg/kg once daily (maximum daily dose 29.4 mg). The duration of treatment was 3 months for all participants. Safety and efficacy were studied after 30 and 90 days of treatment. In addition, fecal calprotectin as a marker of intestinal inflammation was measured simultaneously and compared to the results obtained before therapy. Statistical analysis was performed using the STATA SE v.18 software. The level of statistical significance was set at 0.05. Results: Overall, 56 children were enrolled in the study (median age 7.6 years). Three of them did not complete the designated oral treatment, as they had severe IDA that did not adequately respond to oral iron therapy after 30 days, thus necessitating the administration of parenteral iron. In addition, six patients failed to provide stool samples at 30 and/or 90 days and were also excluded. Hence, the final analysis included 47 patients. Among them, 23 patients were prescribed IPC and 24 SI. Fecal calprotectin levels did not increase compared to baseline measurements in both groups after 90 days of treatment. IPC and SI effectively elevated serum ferritin levels after 30 and 90 days. Median ferritin level at baseline was 6.7 μg/L in the IPC group and 6.6 μg/L in the SI group, increasing to 15.9 μg/L and 12.1 μg/L respectively, after 90 days of treatment (p=0.002 and p=0.001, respectively). Both IPC and SI effectively elevated Hb levels in patients with IDA after 30 (p= 0.003 and p<0.001, respectively) and 90 days of treatment (p=0.002 and p=0.003, respectively). In addition, no differences in the trend over time were observed between the two groups regarding fecal calprotectin, serum ferritin, and Hb. Gastrointestinal adverse events were reported in 5 patients—4 in the IPC group (17.4%) and 1 in the SI group (4.2%) (p = 0.19).Conclusions: Our study showed that oral iron therapy in children with IDA or IDWA does not induce intestinal inflammation, as assessed by fecal calprotectin. The two iron formulations used (SI and IPC) appear to be equivalent in terms of efficacy, as evidenced by comparable increases in Hb and serum ferritin levels between the groups. Although a difference in adverse events was noted—1 patient in the SI group versus 4 in the IPC group—this was not statistically significant, likely due to the small sample size. These findings indicate that SI may represent a safe and effective alternative to IPC.
Degree
thesis:*- Grantor dc:publisher
- Democritus University of Thrace (DUTH)
- Year dc:date
- 2025
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Alexiadou, Sonia
- Αλεξιάδου, Σόνια
Subjects
dc:subject × 16- Σιδηροπενία
- Σιδηροπενική αναιμία
- Καλπροτεκτίνη κοπράνων
- Φλεγμονή εντέρου
- Iron deficiency
- Iron deficiency anemia
- Fecal calprotectin
- Intestinal inflammation
- Κλινική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Παιδιατρική, Νεογνολογία και Υγεία του παιδιού
- Αιματολογία
- Clinical Medicine
- Medical and Health Sciences
- Pediatrics, Perinatology and Child Health
- Hematology
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/59387